Health Research Desk

What Is Candida auris? Why the Drug-Resistant Fungus Can Hide in Hair Follicles and Keep Spreading Through Hospitals

Candida auris is a drug-resistant fungus that spreads primarily through healthcare facilities, often by colonizing people who have no symptoms. A peer-reviewed study published in Science in August 2026 identifies one mechanism that may help explain why the organism can remain on skin for extended periods: in mice, C. auris persisted inside hair follicles by suppressing the immune defenses normally used to clear fungi.

Health Research · August 11, 2026 · KG-CAURIS-001 · Last Verified August 11, 2026

This report was developed from POPR's final sealed Candida auris knowledge graph (KG-CAURIS-001, v2), reconciled against the August 2026 Science study, CDC Candida auris surveillance, CDC National Notifiable Diseases Surveillance System tables, CDC antimicrobial-resistance research and current clinical guidance. Clinical infections, screening detections, colonization, antifungal resistance and preclinical findings are kept separate throughout because combining those categories can materially distort the public picture of the outbreak.

Candida auris Drug-Resistant Fungus Hides in Hair Follicles Spreads in Hospitals POPR Newsroom Verified Report bold white type on navy background

Candida auris has become one of the most difficult fungal threats facing hospitals and long-term healthcare facilities, and the reason is more complicated than antifungal resistance alone. The organism can live on a patient's skin without causing symptoms, remain there for months or potentially longer, contaminate healthcare environments and move between facilities with colonized patients who may never know they are carrying it. (CDC, Preventing the Spread of C. auris; CDC, About C. auris) That persistent human reservoir is central to understanding the current Candida auris story, and the August 2026 Science paper provides an important biological clue. Researchers found that C. auris can persist in mouse hair follicles by exposing a component of its cell wall called chitin and provoking an interferon-gamma-dominated immune response. Instead of producing the more protective type 3/17 antifungal response observed against Candida albicans, the skin generated an immune environment that made C. auris harder to clear. (Merrill et al., Science, August 2026) The discovery does not mean researchers have solved every aspect of Candida auris colonization, and the mechanism has not yet been demonstrated identically in living human carriers, but it does help explain one of the characteristics that makes the organism unusually difficult to eradicate. Persistent skin colonization can provide a healthcare pathogen with a durable biological reservoir even when the person carrying it is not visibly sick.

What Is Candida auris?

Candida auris, also recognized in some scientific nomenclature as Candidozyma auris, is an emerging yeast capable of causing serious invasive infections and healthcare-associated outbreaks. Unlike many familiar Candida infections, C. auris is particularly concerning because it can spread efficiently between patients and healthcare environments, persist on skin and surfaces and resist multiple antifungal medications. (CDC, About C. auris; CDC, Identification of C. auris)

The epidemiological pattern is primarily healthcare-associated rather than a broad community epidemic. CDC says people without relevant risk factors generally do not become infected or colonized. The greatest risk is concentrated among people who are already seriously ill, have prolonged or frequent healthcare exposure, have weakened immune systems or use invasive medical devices such as breathing tubes, feeding tubes or central venous catheters. (CDC, About C. auris; CDC, Clinical Overview of Candida auris) That distinction matters because descriptions of a superbug spreading across America can make C. auris sound like an organism healthy people are routinely acquiring through ordinary daily contact, which is not the pattern CDC describes. The threat is serious precisely because the organism circulates inside environments containing the people most vulnerable to invasive infection.

What Did Scientists Discover About Candida auris and Hair Follicles?

The August 2026 Science study examined why Candida auris can remain on skin much longer than other fungal species that the immune system clears more effectively. Researchers compared C. auris with Candida albicans in mice. C. albicans provoked the IL-17-associated antifungal immune response that normally helps clear fungal colonization from skin. C. auris produced a markedly different response. (Merrill et al., Science, August 2026)

The researchers found that C. auris exposed chitin in its cell wall in response to skin-associated conditions, and that chitin triggered a type 1 immune response dominated by interferon gamma, or IFNγ. The resulting immune environment suppressed the more protective antifungal response and allowed the fungus to persist inside hair follicles. The process should not be described as the fungus consciously tricking or hijacking the immune system: it is a biological interaction in which molecular signals from the organism produce a host response that is less effective at eliminating it. (Merrill et al., Science, August 2026) The study provides a mechanistic explanation for persistent colonization, but its principal experiments were performed in mice. Separate research involving human keratinocytes and fibroblasts shows that human skin cells mount distinct responses to C. auris, strengthening the biological relevance of skin immunity to the problem, while not establishing that the exact hair-follicle and IFNγ mechanism operates identically inside living human carriers. (Seiser et al., Journal of Investigative Dermatology, 2026) The finding is therefore significant, but the species boundary remains intact.

Why Does Living in Hair Follicles Matter?

A patient does not need to have an active Candida auris infection to help sustain transmission. A person can become colonized, meaning C. auris is present on the skin or another body site without invading tissue and causing illness, and colonized people may have no symptoms whatsoever. (CDC, Preventing the Spread of C. auris)

Colonization is nevertheless clinically important. CDC warns that both infected and colonized patients can shed C. auris into the healthcare environment, where the organism can contaminate bedrails, medical equipment and other surfaces before spreading to additional vulnerable patients. (CDC, Infection Control Guidance; CDC, Preventing the Spread of C. auris) CDC also notes that patients can remain colonized for many months and possibly indefinitely, and for that reason the agency recommends maintaining appropriate transmission precautions during future inpatient healthcare stays even after an earlier clinical infection has resolved. Hair follicles therefore matter not because C. auris is necessarily causing a conventional scalp infection, but because they may provide one protected biological location contributing to long-term carriage. A persistent carrier can become part of a transmission chain moving from patient to room, room to equipment, equipment to another patient and eventually between healthcare facilities as colonized patients are transferred, which helps explain why Candida auris can behave less like an isolated hospital infection and more like a persistent healthcare-network ecology.

What Is the Difference Between Candida auris Colonization and Infection?

Colonization means the organism is present without causing active disease. Clinical infection means the fungus has invaded tissue, bloodstream or another normally sterile body site and is producing illness. Those categories are medically different and should not be used interchangeably. A colonized patient may feel completely normal while still carrying and transmitting the organism, while a patient with invasive infection can become critically ill and require antifungal treatment. (CDC, Preventing the Spread of C. auris; CDC, Clinical Treatment of C. auris Infections)

CDC does not recommend antifungal treatment merely because someone is colonized without signs or symptoms of infection. Treatment is directed toward clinical infection, while colonization is managed primarily through infection-control practices intended to prevent transmission. (CDC, Clinical Treatment of C. auris Infections) The same distinction is critical when interpreting national case counts, because much of the confusion surrounding current Candida auris statistics comes from reporting that combines clinical cases with screening cases even though CDC tracks them separately.

Does Texas Really Have the Most Candida auris Cases?

Not if the question is clinical infections. CDC maintains separate surveillance categories for clinical cases and screening cases. Screening cases generally identify C. auris through colonization surveillance rather than representing confirmed clinical illness. CDC began publishing Candida auris screening as a separate nationally notifiable condition in 2023. (CDC, NNDSS Notice to Data Users)

For the week ending July 18, 2026, CDC's provisional surveillance reported 3,130 confirmed screening cases nationally. Texas accounted for 706 of those screening detections, the largest screening total in the country. (CDC, NNDSS Week 28 provisional surveillance, 2026) That figure has appeared prominently in current coverage, but it is not the number of Texans with confirmed clinical Candida auris infections. For the corresponding surveillance period, CDC reported 3,302 confirmed clinical cases nationally. California led the clinical count with 826, while Texas reported 391. Saying that Texas led the country with more than 700 Candida auris infections converts colonization screening detections into confirmed clinical illness. Both categories matter, but they describe different populations and different stages of the public-health problem.

Why Are Different Candida auris Case Numbers Being Reported?

CDC publishes multiple legitimate datasets serving different surveillance purposes. The agency's live tracking page reports 6,304 clinical Candida auris cases during 2024. (CDC, Tracking C. auris) Its finalized MMWR surveillance analysis reports 6,197 clinical cases for the same year and 13,507 clinical cases nationally from 2022 through 2024, with the finalized report recording 2,882 cases in 2022, 4,428 in 2023 and 6,197 in 2024. (Gold et al., MMWR Surveillance Summaries, 2026) Both figures come from CDC, but they arise from different reporting instruments and stages of data reconciliation.

The finalized surveillance record shows that clinical cases increased substantially across the period. CDC also emphasizes an important qualification: cases continue rising, but the rate of annual increase has slowed since 2022. (CDC, Tracking C. auris; Gold et al., MMWR Surveillance Summaries, 2026) That produces a more accurate picture than simply saying Candida auris cases are exploding. The organism remains a growing healthcare problem, while the annual growth rate itself has not continued accelerating without interruption.

How Drug-Resistant Is Candida auris?

Candida auris is highly resistant to some antifungal drugs, but most infections are not untreatable. CDC's Antimicrobial Resistance Laboratory Network tested 8,033 clinical C. auris isolates collected during 2022 and 2023. Approximately 95 percent were resistant to fluconazole, 15 percent were resistant to amphotericin B and 1 percent were resistant to echinocandins. Fewer than 1 percent were resistant across all three major antifungal classes. (Laury et al., Emerging Infectious Diseases, February 2026)

Those percentages require an important methodological caveat. The AR Lab Network is designed primarily to support local detection, outbreak response and public-health testing, and the study's authors explicitly caution that the isolates should not automatically be treated as a nationally representative random sample of every C. auris infection in the United States. (Laury et al., Emerging Infectious Diseases, February 2026) A separate CDC genomic study reported echinocandin resistance among roughly 7 percent of 809 isolates tested in another sampling effort. That does not mean one CDC study found 1 percent resistance while another discovered the true figure was seven times higher. The genomic study intentionally included unusual and epidemiologically important isolates, including resistant organisms, producing a sample more enriched for resistance than broader testing, and the two percentages should not be treated as directly interchangeable because sampling design changes the question being answered. (CDC/Emerging Infectious Diseases, Updated Genomic Epidemiologic Description, 2026) The clinically important point is that echinocandin resistance remains relatively uncommon in the broader AR Lab Network data, and CDC continues to recommend echinocandins as initial therapy for most C. auris infections. (CDC, Clinical Treatment of C. auris Infections) The claim that most Candida auris infections cannot be treated is therefore not supported.

Can Candida auris Become Resistant to Every Major Antifungal?

Yes, but those cases remain uncommon. Pan-resistant Candida auris, meaning resistance across the major antifungal classes used against it, has been documented, and CDC treats the emergence of these isolates as a serious public-health concern because treatment options become extremely limited when echinocandin resistance occurs alongside azole and amphotericin resistance. (CDC, MMWR, Candida auris Isolates Resistant to Three Classes) In the 8,033-isolate AR Lab Network study, fewer than 1 percent of isolates were resistant across all three major antifungal classes, which means "drug-resistant" and "untreatable" are not synonymous. (Laury et al., Emerging Infectious Diseases, February 2026)

How Dangerous Is Candida auris Infection?

Invasive Candida auris infection can be extremely serious, particularly because it usually occurs in patients who are already medically fragile. A U.S. analysis covering 192 C. auris-associated hospitalizations from 2017 through 2022 estimated crude mortality at approximately 34 percent, with mortality approximately 47 percent among bloodstream cases and 31 percent among non-bloodstream cases, while in-hospital mortality specifically was approximately 21 percent. (Benedict et al., Emerging Infectious Diseases, 2023)

Those figures should not be interpreted as the probability that Candida auris itself will kill an otherwise healthy person who acquires it. Patients represented in these studies commonly had serious concurrent medical conditions and extensive healthcare exposure, and mortality observed among patients with C. auris is not equivalent to mortality caused solely by C. auris. Claims that Candida auris causes approximately 3,000 U.S. deaths every year were also reviewed during POPR's verification process but could not be traced to a specific primary CDC source, and that figure is therefore not treated as an established fact in this report. The verified mortality evidence among vulnerable patients is already serious without attaching an unconfirmed national death estimate to it.

Should Healthy People Be Worried About Candida auris?

For most healthy people without substantial healthcare exposure or relevant medical risk factors, CDC says the risk is low. The organism spreads primarily in healthcare environments and disproportionately affects people who are already seriously ill, immunocompromised or exposed to invasive medical devices and prolonged healthcare care. (CDC, About C. auris; CDC, Clinical Overview of Candida auris) Low risk should not be transformed into an absolute claim of zero risk, but neither should a serious healthcare-associated outbreak be presented as a broad community epidemic. For the general population, the most accurate framing is that Candida auris represents a major healthcare infection-control threat concentrated among medically vulnerable people rather than a fungus spreading indiscriminately through ordinary community contact.

Why Is Candida auris So Difficult for Hospitals to Eliminate?

The organism can survive in two interconnected reservoirs: patients and the healthcare environment. Colonized patients can carry C. auris for extended periods and repeatedly shed it onto surrounding surfaces and equipment. The fungus can then persist in the environment and move through contact with contaminated objects or other patients. (CDC, Preventing the Spread of C. auris; CDC, Infection Control Guidance)

Healthcare networks also move patients between facilities. A person may receive treatment in an acute-care hospital, transfer to a long-term acute-care hospital, enter a skilled nursing facility, receive dialysis elsewhere and later return to another hospital. If colonization follows that patient through those transitions, the organism is no longer restricted to one room or one building but can move through a regional healthcare network. Infection-control teams therefore treat colonization as consequential even when the person has no symptoms, and the biological persistence revealed by the new hair-follicle research may help explain why a colonized patient can remain a transmission reservoir long enough for healthcare movement itself to become part of the organism's ecology. (Merrill et al., Science, August 2026; CDC, Preventing the Spread of C. auris; CDC, Infection Control Guidance)

Can Colonization Eventually Turn Into an Infection?

It can in some patients. CDC researchers examined 21,195 U.S. patients who tested positive for Candida auris colonization during 2016 through 2023. Approximately 6.9 percent were subsequently found to have a positive clinical specimen, including 2.8 percent with a positive blood specimen. (Baker et al., Emerging Infectious Diseases, 2025)

Most patients in the analysis did not become clinical cases, so the data do not mean every colonized patient is progressing toward invasive infection. The study does show why colonization matters beyond transmission alone: in medically vulnerable patients, carrying the organism can create a reservoir from which clinical infection may later emerge, which is one reason safe and effective decolonization remains an important unsolved problem.

Does the New Hair-Follicle Discovery Point Toward a Treatment?

It identifies therapeutic hypotheses rather than available treatments. The Science researchers describe two broad approaches suggested by the mechanism they discovered. One would attempt to shift the immune response away from the interferon-gamma-dominated state and toward the more protective IL-17-associated antifungal response. Another would attempt to interfere with the chitin exposure that helps initiate the counterproductive immune response. (Merrill et al., Science, August 2026) Neither approach is currently an established Candida auris therapy, and the study identifies biological targets for future investigation rather than a drug that hospitals can currently use to clear colonized patients.

If researchers eventually develop a safe way to eliminate persistent skin colonization, the consequences could extend beyond the individual patient because reducing the human reservoir might also reduce onward healthcare transmission. That remains a research possibility, not a demonstrated clinical outcome.

Is There a Candida auris Vaccine?

There is no approved human Candida auris vaccine. A 2026 study in npj Vaccines evaluated beta-glucan chitosan particles as an experimental vaccine candidate against multidrug-resistant C. auris. Vaccinated mice generated antibody and T-cell responses, showed lower fungal burden in target organs and had 40 percent survival after disseminated infection compared with zero survival in the placebo group under the study conditions. (Singh et al., npj Vaccines, 2026)

That is meaningful preclinical evidence, but it remains animal research and does not show that a Candida auris vaccine is available, nor does it establish how effectively the same approach would work in humans. What it demonstrates is that researchers are attacking the problem from several directions simultaneously: treatment of invasive infection, persistent colonization, transmission prevention and potential vaccination.

Why the New Science Changes the Candida auris Story

The most important finding from the August study is not simply that researchers found C. auris in hair follicles. The work connects a molecular mechanism to a larger epidemiological problem. Candida auris can persist on skin. Persistent colonization creates asymptomatic carriers. Those carriers can contaminate healthcare environments. Healthcare environments expose medically vulnerable patients. Patient transfers can move the organism between facilities. Some colonized patients later develop clinical infection. Antifungal exposure can then add selective pressure to an organism already notable for drug resistance. (Merrill et al., Science, August 2026; CDC, Preventing the Spread of C. auris; CDC, Infection Control Guidance; Laury et al., Emerging Infectious Diseases, February 2026; Baker et al., Emerging Infectious Diseases, 2025)

The hair-follicle discovery therefore helps explain part of the biological foundation beneath a much larger healthcare transmission system. Candida auris is difficult to control not only because it can resist antifungal medications, but because it can remain biologically attached to people without making them visibly sick, and that combination gives the organism the time it needs to move.

What the Current Numbers Actually Say

The United States is experiencing a genuine rise in Candida auris. CDC's finalized surveillance recorded 13,507 clinical cases from 2022 through 2024, increasing from 2,882 in 2022 to 4,428 in 2023 and 6,197 in 2024. CDC's live tracking system separately lists 6,304 clinical cases for 2024. (Gold et al., MMWR Surveillance Summaries, 2026; CDC, Tracking C. auris) Provisional 2026 surveillance continues to show thousands of clinical cases and screening detections, but those categories must be reported accurately. Clinical cases track infection-related detections. Screening cases primarily identify colonization. In CDC's Week 28 provisional data, California led confirmed clinical cases at 826. Texas reported 391 clinical cases while leading the separate screening category with 706 detections. (CDC, NNDSS Week 28 provisional surveillance, 2026)

That correction changes the interpretation without minimizing the scale of the problem. More than 700 colonization detections in one state can still represent a serious healthcare transmission challenge, and it simply should not be transformed into more than 700 confirmed clinical infections. The distinction between colonization and infection is not statistical bookkeeping. It is the architecture of the Candida auris problem.

Fact Summary

What is Candida auris? Candida auris is an emerging, frequently drug-resistant fungus that causes healthcare-associated outbreaks and can produce serious invasive infections, particularly in medically vulnerable patients. (CDC, About C. auris)

Can Candida auris live in hair follicles? In an August 2026 Science study, C. auris persisted in mouse hair follicles through a mechanism involving exposed chitin and an interferon-gamma-dominated immune response. The identical mechanism has not yet been demonstrated directly in living human carriers. (Merrill et al., Science, August 2026)

Is colonization the same as infection? No. Colonized people carry C. auris without active illness but can still spread it. Clinical infection means the organism is causing disease. (CDC, Preventing the Spread of C. auris; CDC, Clinical Treatment of C. auris Infections)

Does Texas have the most Candida auris infections? Not in CDC's Week 28 clinical surveillance. California led confirmed clinical cases at 826. Texas reported 391 confirmed clinical cases while leading the separate screening category with 706 detections. (CDC, NNDSS Week 28 provisional surveillance, 2026)

How many clinical cases did the United States report in 2024? CDC's live tracking page reports 6,304 clinical cases. Its finalized MMWR surveillance analysis reports 6,197 for the same year. The difference reflects separate CDC reporting instruments and stages of surveillance reconciliation. (CDC, Tracking C. auris; Gold et al., MMWR Surveillance Summaries, 2026)

How resistant is Candida auris? Among 8,033 clinical isolates tested through CDC's AR Lab Network during 2022 and 2023, 95 percent were fluconazole resistant, 15 percent amphotericin B resistant and 1 percent echinocandin resistant. The sample was designed for detection and outbreak response rather than nationally representative prevalence estimation. (Laury et al., Emerging Infectious Diseases, February 2026)

Is Candida auris untreatable? Usually not. Echinocandins remain CDC's recommended initial treatment for most clinical infections, although resistant and rare pan-resistant cases do occur. (CDC, Clinical Treatment of C. auris Infections)

Are healthy people at high risk? No. CDC says risk is low for people without relevant healthcare or medical risk factors. C. auris primarily threatens patients who are already seriously ill or have substantial healthcare exposure. (CDC, About C. auris; CDC, Clinical Overview of Candida auris)

Can colonization later become clinical infection? Yes, in some patients. A CDC analysis found that 6.9 percent of 21,195 colonized patients later had a positive clinical specimen, including 2.8 percent with a positive blood specimen. (Baker et al., Emerging Infectious Diseases, 2025)

Is there a Candida auris vaccine? No approved human vaccine exists. A 2026 mouse study reported immune responses and improved survival from an experimental beta-glucan chitosan particle vaccine candidate, but the work remains preclinical. (Singh et al., npj Vaccines, 2026)

Sources

Merrill, E. D., Prudent, V., Basso, P., et al. "The fungal pathogen Candida auris exposes chitin to trigger IFNγ and persist in hair follicles." Science, 393(6811), eadu6688. August 6, 2026. DOI: 10.1126/science.adu6688.

Centers for Disease Control and Prevention. "Tracking C. auris" and "About C. auris." CDC

Centers for Disease Control and Prevention. "Preventing the Spread of C. auris." CDC

Centers for Disease Control and Prevention. "Identification of C. auris." CDC

Seiser, S., et al. "Human keratinocytes and fibroblasts coordinate early cutaneous innate defenses against Candida auris." Journal of Investigative Dermatology. 2026.

Centers for Disease Control and Prevention. "Infection Control Guidance: Candida auris." CDC

Centers for Disease Control and Prevention. "Clinical Treatment of C. auris Infections." CDC

Centers for Disease Control and Prevention. National Notifiable Diseases Surveillance System. "Notice to Data Users and Publication Criteria." CDC

Centers for Disease Control and Prevention. National Notifiable Diseases Surveillance System. Candida auris clinical and screening surveillance. Week 28, week ending July 18, 2026. CDC

Centers for Disease Control and Prevention. "Tracking C. auris." Live surveillance page. CDC

Gold, J. A. W., et al. "Surveillance for Candida auris, United States, 2022–2024." Morbidity and Mortality Weekly Report: Surveillance Summaries. 2026.

Laury, J. E., Forsberg, K., Berkow, E. L., et al. "Candida auris Testing by the Antimicrobial Resistance Laboratory Network, United States, 2022–2023." Emerging Infectious Diseases. 32(2). February 2026. DOI: 10.3201/eid3202.251043.

Centers for Disease Control and Prevention / Emerging Infectious Diseases. "Updated Genomic Epidemiologic Description of Candida auris." 2026.

Centers for Disease Control and Prevention. "Candida auris Isolates Resistant to Three Classes of Antifungal Medications." MMWR. CDC

Benedict, K., et al. "Candida auris–Associated Hospitalizations, United States, 2017–2022." Emerging Infectious Diseases. 2023.

Centers for Disease Control and Prevention. "Clinical Overview of Candida auris." CDC

Baker, A. D., et al. "Progression from Candida auris Colonization Screening to Clinical Case Status, United States, 2016–2023." Emerging Infectious Diseases. 31(8). 2025.

Singh, S., Barbarino, A., Youssef, E. G., et al. "β-Glucan chitosan particle provides cross-protection against multi-drug-resistant Candida auris." npj Vaccines. 2026. DOI: 10.1038/s41541-026-01485-x.

Evidence Status

CONFIRMED: Candida auris is a rising, frequently drug-resistant healthcare-associated fungal threat in the United States. (CDC, Tracking C. auris; Gold et al., MMWR Surveillance Summaries, 2026) CONFIRMED: The August 2026 Science study identified a chitin-triggered, IFNγ-associated mechanism that enabled C. auris to persist in mouse hair follicles. (Merrill et al., Science, August 2026) CONFIRMED: Colonization and clinical infection are distinct states. Colonized patients can remain asymptomatic while continuing to spread the organism. (CDC, Preventing the Spread of C. auris; CDC, Infection Control Guidance) CONFIRMED: CDC surveillance maintains clinical and screening Candida auris cases as separate categories. The widely reported Texas figure of 706 in Week 28 represented screening detections rather than confirmed clinical infections. California led confirmed clinical cases at 826. Texas reported 391 confirmed clinical cases. (CDC, NNDSS Week 28 provisional surveillance, 2026) CONFIRMED: CDC's AR Lab Network study of 8,033 clinical isolates found 95 percent fluconazole resistance, 15 percent amphotericin B resistance and 1 percent echinocandin resistance. The sample was designed for detection and outbreak response rather than nationally representative prevalence estimation. (Laury et al., Emerging Infectious Diseases, February 2026) CONFIRMED WITH SAMPLING CAVEAT: A separate CDC genomic dataset reported approximately 7 percent echinocandin resistance in a sample enriched for epidemiologically significant and unusual isolates. That result should not be treated as contradictory to the 1 percent broader AR Lab Network estimate or generalized to all U.S. cases. (CDC/Emerging Infectious Diseases, Updated Genomic Epidemiologic Description, 2026) CONFIRMED: Echinocandins remain CDC's recommended initial treatment for most Candida auris infections. (CDC, Clinical Treatment of C. auris Infections) CONFIRMED: Current evidence indicates low risk to healthy people without relevant healthcare or medical risk factors. (CDC, About C. auris; CDC, Clinical Overview of Candida auris) PRECLINICAL: The hair-follicle mechanism was established primarily in mice. Separate human-cell research supports biological relevance but does not establish identical behavior in living human carriers. (Merrill et al., Science, August 2026; Seiser et al., Journal of Investigative Dermatology, 2026) PRECLINICAL: A beta-glucan chitosan particle vaccine candidate produced immune responses and improved survival in mice. It is not an approved or demonstrated human vaccine. (Singh et al., npj Vaccines, 2026) NOT ESTABLISHED: That Texas currently leads the nation in confirmed clinical Candida auris infections; that healthy people face substantial community risk; that the mouse hair-follicle mechanism operates identically in humans; that the 1 percent and 7 percent echinocandin-resistance estimates represent contradictory national prevalence measures; or that Candida auris causes a verified 3,000 U.S. deaths per year.

Key Questions

What is Candida auris?

Candida auris is an emerging, frequently drug-resistant fungus that causes healthcare-associated outbreaks and can produce serious invasive infections, particularly in medically vulnerable patients.

Can Candida auris live in hair follicles?

In an August 2026 Science study, C. auris persisted in mouse hair follicles through a mechanism involving exposed chitin and an interferon-gamma-dominated immune response. The identical mechanism has not yet been demonstrated directly in living human carriers.

Is colonization the same as infection?

No. Colonized people carry C. auris without active illness but can still spread it. Clinical infection means the organism is causing disease.

Does Texas have the most Candida auris infections?

Not in confirmed clinical cases. In CDC's Week 28 provisional data, California led confirmed clinical cases at 826. Texas reported 391 confirmed clinical cases while leading the separate screening category with 706 detections.

How many clinical cases did the United States report in 2024?

CDC's live tracking page reports 6,304 clinical cases. Its finalized MMWR surveillance analysis reports 6,197 for the same year. The difference reflects separate CDC reporting instruments and stages of surveillance reconciliation.

How resistant is Candida auris to antifungal drugs?

Among 8,033 clinical isolates tested through CDC's AR Lab Network during 2022 and 2023, 95 percent were fluconazole resistant, 15 percent amphotericin B resistant and 1 percent echinocandin resistant. The sample was designed for detection and outbreak response rather than nationally representative prevalence estimation.

Is Candida auris untreatable?

Usually not. Echinocandins remain CDC's recommended initial treatment for most clinical infections, although resistant and rare pan-resistant cases do occur.

Are healthy people at high risk from Candida auris?

No. CDC says risk is low for people without relevant healthcare or medical risk factors. C. auris primarily threatens patients who are already seriously ill or have substantial healthcare exposure.

Can colonization later become clinical infection?

Yes, in some patients. A CDC analysis found that 6.9 percent of 21,195 colonized patients later had a positive clinical specimen, including 2.8 percent with a positive blood specimen.

Is there a Candida auris vaccine?

No approved human vaccine exists. A 2026 mouse study reported immune responses and improved survival from an experimental beta-glucan chitosan particle vaccine candidate, but the work remains preclinical.